A few years ago, a group of diabetes medicines turned out to do something their makers had not built a business around: they caused substantial weight loss. Demand exploded, supply could not keep up, and a corner of the drug industry became one of the most-watched stories in the market. These are the GLP-1 stocks — and the boom around them now reaches far beyond the two companies that started it, into manufacturing, devices, retail, food, and the rest of healthcare.
This series maps that reach. It is a companion to our Healthcare Sector series, zoomed in on a single, fast-moving theme. Two ground rules first: this is not medical advice — we will not discuss how to take these drugs or who should — and it is not investment advice. The aim is to explain the businesses clearly, both their opportunities and their risks, so you can read the next headline knowing exactly what it affects.
Where this sits: the ripple
Picture a stone dropped into water. The drug is the stone; the rings spread outward:
Duopoly → Pill → Factory → Delivery → Access → Consumer ripple · Healthcare ripple → Forces
The inner rings are the value chain — who makes the drug and how it reaches a patient. The outer rings are the knock-on effects — who else, across the economy, wins or loses. Each ring is its own article:
- The Duopoly — the two companies, Eli Lilly and Novo Nordisk, that built and still dominate the market.
- The Pill — the oral race and next-generation drugs aiming to break that duopoly.
- The Factory — why making the drug, not selling it, has been the real bottleneck.
- The Delivery — the pens, needles, and components behind every injection.
- The Access Layer — telehealth, compounding, and cash-pay: how patients actually get the drugs.
- The Consumer Ripple — the debate over whether GLP-1s dent demand for food, drink, and dining.
- The Healthcare Ripple — the knock-on effects on diabetes devices, sleep apnea, and more.
- The Forces — what could make or break the whole boom.
What a GLP-1 drug actually is
In plain terms, a GLP-1 receptor agonist mimics a natural gut hormone that helps regulate blood sugar and signals fullness. The result is better blood-sugar control and reduced appetite. Two molecules dominate today:
- Semaglutide, made by Novo Nordisk — sold as Ozempic for diabetes and Wegovy for weight management.
- Tirzepatide, made by Eli Lilly — sold as Mounjaro for diabetes and Zepbound for weight management.
For years these were weekly injections. That changed in early 2026: Novo launched an oral semaglutide pill, and Lilly's oral drug orforglipron won US approval in April 2026. The arrival of pills is the single biggest shift in the story, and it runs through several pieces in this series.
How big is the market, really?
This is the question under every company in the series, and the honest answer is that experts disagree sharply. Goldman Sachs trimmed its forecast to roughly $95 billion by 2030 (with a US peak near $70 billion); other analysts hold higher — GlobalData around $111 billion by 2033, and some banks near $150 billion in the early 2030s. The range itself is the point: this is a young, fast-changing market, and reasonable people model it very differently. We return to that disagreement in The Forces.
If you are not in the US
Most readers here are not American, so a few standing notes:
- The two leaders are global. One is American (Eli Lilly); the other, Novo Nordisk, is Danish — listed on its home market and accessible to US investors through a US-listed receipt (an ADR), whose value also moves with the euro/krone-to-dollar exchange rate.
- Pricing and insurance coverage are largely a US story; how these drugs are paid for where you live may be entirely different.
- What you can buy, and how it is taxed, depends on your country. Treat anything that sounds practical as something to check locally.
The takeaways
- GLP-1 stocks centre on two companies and two molecules, but the boom reaches across the economy.
- The market is large and growing, but its eventual size is genuinely uncertain — forecasts range from about $95 billion to $150 billion-plus.
- The shift from injections to pills, beginning in 2026, is reshaping who wins.
- This is a map for understanding the businesses — not medical or financial advice.
The tour starts at the centre of the ripple: the two companies that own the market. Next, The Duopoly.
This article is for information only. It is not medical advice and not investment advice or a recommendation to buy or sell any security. TradeRadarNews is not a licensed financial or medical adviser. Figures are accurate as of June 2026 and will change. Markets carry risk, including loss of capital. Rules, taxes, and available products differ by country — do your own research and consult a locally regulated professional.